RxDoctor Payments Data

Megan Benda, PA

Physician Assistant · Vero Beach, FLNPI 1861940421

Payments from drug & device makers

$1,585in general payments, 2019–2025

Across 65 payments — averaging $24.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$681
  • Teva Pharmaceuticals USA, Inc.$178
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$147
  • Vanda Pharmaceuticals Inc.$135
  • Livanova USA, Inc.$117
  • Neurocrine Biosciences, Inc.$81
  • plus $246 from 6 others

What the payments were for

  • Food & beverage$1,585100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,585 in reported general payments places this provider in the 70th percentile of 8,062 physician assistant providers in Florida.

See all physician assistant providers in Florida

Medicare billing

Part B allowed, 2024
$41,131
Medicare patients
57
Services billed
467

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl12$22,858
Paliperidone ErPaliperidone11$2,270
Duloxetine Hcl35$1,249
Fluoxetine Hcl35$1,014
Venlafaxine Hcl ErVenlafaxine Hcl54$980
Aripiprazole30$854
Lamotrigine26$461
Trazodone Hcl37$453
Mirtazapine13$416
Clonazepam40$335
Quetiapine Fumarate34$323
Escitalopram Oxalate29$318
Bupropion XlBupropion Hcl14$312
Hydroxyzine Hcl16$311
Buspirone Hcl11$209

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$681$22,85812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,062 physician assistant providers in Florida.

Other physician assistant in Vero Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →